Tag: Roswell Park Comprehensive Cancer Center

Oncotarget Sponsors Open Access Team in 2025 Ride for Roswell

June 10, 2025

Impact Journals, the publisher of Oncotarget, is once again proudly sponsoring the Open Access Team in the annual Ride for Roswell. BUFFALO, NY — June 10, 2025 — The Ride… read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,… read more

Oncotarget

Ride for Roswell 2023: Team Open Access Recap

June 26, 2023

In a remarkable achievement, Oncotarget and Team Open Access contributed to an impressive total raise of $5.6 million (and the amount continues to grow) for cancer research through the Ride… read more

Oncotarget

Why We Ride: Misha Pletnikov

June 23, 2023

My name is Misha Pletnikov, I am chair of the department of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences of the University at Buffalo. I… read more

Oncotarget

Oncotarget Sponsors 2023 Ride for Roswell

June 19, 2023

Oncotarget's publisher, Impact Journals, is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer… read more

Figure 2: Polyclonal, Clonal and Restricted Repertoire Phenotypes in Clonality Testing.

Oncotarget

Automated, Accurate Reporting for NGS-Based Clonality Testing

May 16, 2023

“[...] we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.” Listen to… read more

Figure 2: Rapamycin prevents cancer by slowing tumor progression (hypothetical schema).

Oncotarget

Cancer Prevention With Rapamycin

April 17, 2023

“[...] long-term treatment with rapamycin slows down aging, a major risk factor for cancer [...]” Listen to an audio version of this press release BUFFALO, NY- April 17, 2023 –… read more

Figure 6: Synergistic/antagonistic combinations.

Oncotarget

Oncotarget | Selective Protection of Normal Cells From Chemotherapy, While Killing Drug-Resistant Cancer Cells

March 13, 2023

“Selective protection of normal cells may transform therapy of cancer.” Listen to an audio version of this press release BUFFALO, NY- March 13, 2023 – A new review paper was… read more

Oncotarget

Oncotarget | Therapeutic Efficacy of Humanized JAA-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

October 25, 2022

“The potential therapeutic efficacy of the humanized antibodies to TF-Ag-α, hJAA-F11-H2aL2a and hJAA-F11-H3L3, was assessed in human breast and lung cancer xenograft models.” Listen to an audio version of this… read more

PRESS RELEASE: Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

Oncotarget

Impact Journals Sponsors 2022 Ride For Roswell

June 14, 2022

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell. Listen to an audio version of this… read more